Title :

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database

Author(s) :

Dalle, Stephane [Auteur]
Varey, Emilie [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre hospitalier universitaire de Nantes [CHU Nantes]
Nguyen, Jean-Michel [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Centre hospitalier universitaire de Nantes [CHU Nantes]
Dupuy, Alain [Auteur]
Centre Eugène Marquis [CRLCC]
Montaudie, Henri [Auteur]
Hôpital l'Archet
Lesage, Candice [Auteur]
Hôpital Saint Eloi [CHRU Montpellier]
Mortier, Laurent [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Leccia, Marie-Thérèse [Auteur]
CHU Grenoble
Skowron, François [Auteur]
Celerier, Philippe [Auteur]
Meyer, Nicolas [Auteur]
Dutriaux, Caroline [Auteur]
CHU Bordeaux [Bordeaux]
Dalac-Rat, Sophie [Auteur]
CHU Dijon
Khammari, Amir [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre hospitalier universitaire de Nantes [CHU Nantes]
Lebbe, Céleste [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Hopital Saint-Louis [AP-HP] [AP-HP]
Dréno, Brigitte [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre hospitalier universitaire de Nantes [CHU Nantes]

Journal title :

European Journal of Dermatology

Pages :

389-396

Publisher :

John Libbey Eurotext

Publication date :

2020-08

ISSN :

1167-1122

English keyword(s) :

BRAF
adjuvant treatment
immunotherapy
melanoma
sentinel lymph node
targeted treatment

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.Objectives: To provide an overview of the management of the French Stage III melanoma population ...
Show more >Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.Objectives: To provide an overview of the management of the French Stage III melanoma population after complete lymph node resection prior to new adjuvant therapies.Materials and methods: A subgroup data analysis.Results: Data from 1,835 patients were analysed (15.58% Stage IIIA, 39.24% Stage IIIB, 43.92% Stage IIIC and 1.25% Stage IIID). Superficial spreading melanoma was the most frequent (70.98% in Stage IIIA for whom mutation analysis was performed; BRAF mutation was identified in up to 62% Stage IIIA patients). Sentinel lymph node biopsy was performed in 88.46% of Stage IIIA patients, 42.36% of Stage IIIB, 53.97% of Stage IIIC and 34.78% of Stage IIID. Up to 80% of Stage IIIA patients had no adjuvant treatment follow-up. Ulceration (p = 0.004; RR: 2.98; 95% CI: 1.4-6.3) and age at diagnosis (p = 0.0002; RR: 1.04; 95% CI: 1.02-1.06) were significant predictive factors for survival. Adjuvant interferon-α was administered in up to 13.04% of Stage IIID patients.Conclusion: Only a small number of Stage III melanoma patients were treated with interferon-α in adjuvant settings. New adjuvant therapies are currently having an effect on clinical practice in France, increasing survival and decreasing cost.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189

Source :

Harvested from HAL